Update on diagnosis, management, and prevention of hepatitis B virus infection

Clinical Microbiology Reviews

Volumn 12, Issue 2, 1999, Pages 351-366

  Mahoney, Francis J ^a,b  

^a US Naval Medical Research Unit No 3 Egypt   (Egypt)

^b US Naval Medical Research Unit No 3   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; FAMCICLOVIR; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE ANALOG;

ACUTE HEPATITIS; CHRONIC HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CANCER; LIVER DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PREVENTIVE HEALTH SERVICE; REVIEW; TAIWAN; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 0032916690     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.12.2.351     Document Type: Review

References (168)

1. Andre, F. E. 1989. Summary of safety and efficacy data on yeast-derived hepatitis B vaccine. Am. J. Med. 87(Suppl.):39-45.
2. Assateerawatt, A., V. S. Tanphaichitr, V. Suvatte, and L. Ingarm. 1991. Immunogenicity and protective efficacy of low dose recombinant DNA hepatitis B vaccine in normal and high-risk neonates. Asian Pac. J. Allergy Immunol. 9:89-93.
3. Averhoff, F., F. J. Mahoney, P. J. Coleman, G. Schatz, E. Hurwitz, and H. S. Margolis. 1998. Risk factors for lack of response to hepatitis B vaccine: a randomized trial comparing the immunogenicity of recombinant hepatitis B vaccines in an adult population. Am. J. Prev. Med. 1:73-77.
4. Barin, F., J. Perrin, J. Chotard, F. Denis, R. N'Doye, I. Diop Mar, J. P. Chiron, and P. Coursaget. 1981. Cross sectional and longtitudinal epidemiology of hepatitis B in Senegal. Prog. Med. Virol. 27:148-162.
5. Beasley, R. P. 1988. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956.
6. Beasley, R. P., and L.-Y. Hwang. 1991. Overview of the epidemiology of hepatocellular carcinoma. The Williams & Wilkins Co., Baltimore, Md.
7. Beasley, R. P., and L. Y. Hwang. 1983. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J. Infect. Dis. 147:185-190.
8. Beasley, R. P., L. Y. Hwang, G. C. Lee, C. C. Lan, C. H. Roan, F. Y. Huang, and C. L. Chen. 1983. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet ii:1099-1102.
9. Beasley, R. P., L. Y. Hwang, C. E. Stevens, C. C. Lin, F. J. Hsieh, K. Y. Wang, T. S. Sun, and W. Szmuness. 1983. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 3:135-141.
10. Bensabeth, G., S. C. Hadler, M. C. Soares, H. Fields, and J. E. Maynard. 1987. Epidemiologic and serologic studies of acute viral hepatitis in Brazil's Amazon Basin. Bull. Pan Am. Health Org. 21:16-27.
11. Bhatnagar, P. K., E. Papas, H. E. Blum, D. R. Milich, D. Nitecki, M. J. Karels, and G. N. Vyas. 1982. Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant. Proc. Natl. Acad. Sci. USA 79:4400-4404.
12. Blumberg, B. S. 1977. Australia antigen and the biology of hepatitis B. Science 197:17-25.
13. Blumberg, B. S., and H. J. Alter. 1967. A "new" antigen in leukemic serum. JAMA 191:541-546.
14. Blumberg, B. S., B. J. Gerstley, D. A. Hungerford, W. T. London, and A. I. Sutnick. 1967. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann. Intern. Med. 66:924-931.
15. Blumberg, B. S., S. Mazzur, K. Hertzog, I. Millman, J. Bloom, and A. Damon. 1974. Australia antigen in the Solomon Islands. Hum. Biol. 46:239-262.
16. Boker, K. H., B. Ringe, M. P. Kruger, and M. P. Manns. 1995. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 57:1706-1708.
17. Carman, W. F., A. R. Zanetti, P. Karayiannis, J. Waters, G. Manzillo, E. Tanzi, A. J. Zuckerman, and H. C. Thomas. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329.
18. Centers for Disease Control and Prevention. Unpublished data.
19. Chan, C. Y., S. D. Lee, Y. T. Tsai, and K. J. Lo. 1991. Booster response to recombinant yeast-derived hepatitis B vaccine in vaccinees whose anti-HBs responses were elicited by a plasma-derived vaccine. Vaccine 9(Suppl. A): 765-767.
20. Chang, M. H., C. J. Chen, M. S. Lai, H. M. Hsu, T. C. Wu, M. S. Kong, D. C. Liang, W. Y. Shau, and D. S. Chen. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336:1855-1859.
21. Chau, K., M. P. Hargie, R. H. Decker, I. K. Mushahwar, and L. R. Overby. 1983. Serodiagnosis of recent hepatitis B virus infection by IgM class anti-HBc. Hepatology 3:142-149.
22. Chen, H. L., M. H. Chang, Y. Ni, H. Y. Hsu, P. I. Lee, C. Y. Lee, and D. S. Chen. 1996. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 276:906-908.
23. Chisari, F., and C. Ferrari. 1995. Hepatitis B virus immunapathogenesis. Annu. Rev. Immunol. 13:29-60.
24. Chisari, F. V. 1997. Cytotoxic T cells and viral hepatitis. J. Clin. Investig. 99: 1472-1477.
25. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
26. Courouce, A. M., A. Loplanche, E. Benhamou, and P. Jungers. 1988. Long term efficacy of hepatitis B vaccination in healthy adults. Alan R. Liss, New York, N.Y.
27. Coursaget, P., D. Leboulleux, M. Soumare, P. le Cann, B. Yvonnet, J. P. Chiron, A. M. Coll-Seck, and I. Diop-Mar. 1994. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J. Hepatol. 21:250-254.
28. Coursaget, P., B. Yvonnet, J. Chotard, M. Sarr, P. Vincelot, R. N'doye, I. Diop-Mar, and J. P. Chiron. 1986. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet ii:1143-1145.
29. Crosnier, J., P. Jungers, A. M. Courouce, A. Laplanche, E. Benhamou, F. Degos, B. Lacour, P. Prunet, Y. Cerisier, and P. Guesry. 1981. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units. I. Medical staff. Lancet i:455-459.
30. Dane, D. S., C. H. Cameron, and M. Briggs. 1970. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet i:695-698.
31. Davidson, M., and S. Krugman. 1986. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J. Infect. 13(Suppl. A):31-38.
32. Desmyter, J., J. De Groote, V. J. Desmet, A. Billiau, M. B. Ray, A. F. Bradburne, V. G. Edy, and P. De Somer. 1976. Administration of human fibroblast interferon in chronic hepatitis B infection. Lancet ii:645-647.
33. Di Bisceglie, A. M. 1988. Hepatocellular carcinoma. Ann. Intern. Med. 108: 390-401.
34. Dientstag, J. L., R. P. Perillo, E. R. Schiff, M. Barthomomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
35. Dodd, R. Y., P. V. Holland, L. Y. Ni, H. M. Smith, and T. J. Greenwalt. 1973. Hepatitis B antigen: regional variation in incidence and subtype ratio in the American Red Cross donor population. Am. J. Epidemiol. 97:111-115.
36. Doong, S.-L., C.-H. Tsai, E. R. Schinazi, D. C. Liotta, and Y.-C. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
37. Eppinger, H. 1922. Die pathogenesis des icterus. Verh. Dtsch. Ges. Inn. Med. 34:15.
38. Flaum, A., H. Malmros, and E. Persson. 1926. Eine nosocomiale icterus-epidemic. Acta Med. Scand. 16:544.
39. Fortuin, M., J. Chotard, A. D. Jack, N. P. Maine, M. Mendy, A. J. Hall, H. M. Inskip, M. O. George, and H. C. Whittle. 1993. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet 341:1129-1131.
40. Francis, D. P., S. C. Halder, S. E. Thompson, J. E. Maynard, D. G. Ostrow, N. Altman, E. H. Braff, P. O'Malley, D. Hawkins, F. N. Judson, K. Penley, T. Nylund, G. Christie, F. Meyers, J. N. Moore, A. Gardner, I. L. Doto, J. H. Miller, G. H. Reynolds, B. L. Murphy, C. A. Schable, B. T. Clark, J. W. Curran, and A. G. Redeker. 1982. Prevention of hepatitis B with vaccine. Report from the Centers for Disease Control multi-center trial among homosexual men. Ann. Intern. Med. 97:362-366.
41. Franks. A. L., C. J. Berg, M. A. Kane, B. B. Browne, R. K. Sikes, W. R. Elsea, and A. H. Burton. 1989. Hepatitis B infection among children born in the U.S. to southeast Asian refugees. N. Engl. J. Med. 321:1301-1305.
42. Freed, G. L., W. C. Bordley, S. J. Clark, and T. R. Konrad. 1993. Reactions of pediatricians to a new CDC recommendation for universal immunization of infants with hepatitis B vaccine. Pediatrics 91:699-702.
43. Freed, G. L., T. R. Konrad, and J. A. Lohr. 1993. Adoption of new haemophilus influenza type b vaccine recommendations. Am. J. Dis. Child. 147:124-128.
44. Ganiats, T. R. 1993. Are we jumping on the bandwagon too early. J. Fam. Pract. 36:147-149.
45. Gerlich, W. H., and V. Bruss. 1993. Functions of hepatitis B virus proteins and molecular targets for protective immunity. Marcel Dekker, Inc., New York, N.Y.
46. Gerlich, W. H., X. Lu, and K. H. Heerman. 1993. Studies on the attachment and penetration of hepatitis B virus. J. Hepatol. 17:S10-S14.
47. Gibas, A., E. Watkins, C. Hinkle, and J. L. Dienstag. 1988. Long term persistence of protective antibody after hepatitis B vaccination of healthy adults. Alan R. Liss, New York, N.Y.
48. Giles, J. P. 1969. Viral hepatitis: relationship of Australia-SH antigen to the Willowbrook MS-2 strain. N. Engl. J. Med. 281:119-122.
49. Goh, K. T., C. J. Oon, B. H. Heng, and B. K. Lim. 1995. Long term immunogenicity and efficacy of a reduced dose of plasma-derived hepatitis B vaccine in young adults. Bull. W. H. O. 73:523-527.
50. Grady, G. F., V. A. Lee, A. M. Prince, G. L. Gitnick, K. A. Fawaz, G. N. Vyas, M. D. Levitt, J. R. Senior, J. T. Galambos, T. E. Bynum, J. W. Singleton, B. F. Clowdus, K. Akdamar, R. D. Aach, E. I. Winkelman, G. M. Schiff, and T. Hersh. 1978. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J. Infect. Dis. 138:625-638.
51. Greenberg, D. P., C. M. Vadheim, V. K. Wong, S. M. Marcy, S. Partridge, T. Greene, C. Y. Chiu, H. S. Margolis, and J. I. Ward. 1996. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr. Infect. Dis. J. 15:590-596.
52. Greenberg, H. B., R. B. Pollard, L. I. Lutwick, P. B. Gregory, W. S. Robinson, and T. S. Merigan. 1976. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N. Engl. J. Med. 295:517-522.
53. Hadler, S. C., D. P. Francis, J. E. Maynard, S. E. Thompson, F. N. Judson, D. F. Echenberg, D. G. Ostrow, P. M. O'Malley, K. A. Penley, and N. L. Altman. 1986. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 315:209-214.
54. Hadler, S. C., F. N. Judson, and P. M. O'Malley. 1990. Studies of hepatitis B vaccine in homosexual men. John Libby, Eurotext, London, United Kingdom.
55. Hadler, S. C., and H. S. Margolis. 1993. Epidemiology of hepatitis B virus infection. Marcel Dekker, Inc., New York, N.Y.
56. Hadler, S. C., and H. S. Margolis. 1992. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization, vol. 12. Blackwell Scientific Publications, Boston, Mass.
57. Hadziyannis, S. J., H. M. Lieberman, G. G. Karvountzis, and D. A. Shafritz. 1983. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs anti-HBe positive carriers of the virus. Hepatology 3:656-662.
58. Harpaz, R. Personal communication.
59. Harpaz, R., L. Von Seidlein, F. M. Averhoff, M. P. Tormey, S. D. Sinha, K. Kotsopoulou, S. B. Lambert, B. H. Robertson, J. D. Cherry, and C. N. Shapiro. 1996. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N. Engl. J. Med. 334:549-554.
60. Harrison, T. J., E. A. Hopes, C. J. Oon, A. R. Zanetti, and A. J. Zuckerman. 1991. Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J. Hepatol. 13(Suppl.):S105-S107.
61. Havens, W. 1946. Period of infectivity of patients with experimentally induced infectious hepatitis. J. Exp. Med. 83:251-258.
62. Hoofnagle, J. H., and A. M. Di Bisceglie. 1991. Serologic diagnosis of acute and chronic viral hepatitis. Semin. Liver Dis. 11:73-83.
63. Hoofnagle, J. H., and A. M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
64. Hoofnagle, J. H., and A. M. Di Biscelgie. 1991. Serologic diagnosis of acute and chronic viral hepatitis. Semin. Liver Dis. 11:73-83.
65. Hoofnagle, J. H., and L. B. Seef. 1982. Natural history of chronic type B hepatitis. Prog. Liver Dis. 7:469-479.
66. Horowitz, M. M., W. B. Ershler, W. P. McKinney, and R. J. Battiola. 1988. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann. Intern. Med. 108:185-189.
67. Howard, C. R. 1995. The structure of hepatitis B envelope and molecular variants of hepatitis B virus. J. Viral Hepatitis 2:165-170.
68. Hsieh, C. C., A. Tzonou, X. Zavitsanos, E. Kalamani, S. J. Lan, and D. Trichopoulos. 1992. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: a birth order study. Am. J. Epidemiol. 136:1115-1121.
69. Hu, M. D., D. Schenzle, F. Dienhart, and R. Scheid. 1984. Epidemiology of hepatitis A and B in Shanghai area: prevalence of serum markers. Am. J. Epidemiol. 120:404-413.
70. Hurie, M. B., E. E. Mast, and J. P. Davis. 1992. Horizontal transmission of hepatitis B virus infection to U.S. born children of Hmong refugees. Pediatrics 89:269-273.
71. Hwang, L. Y., C. Y. Lee, and R. P. Beasley. 1991. Five year follow-up of HBV vaccination with plasma-derived vaccine in neonates: evaluation of immunogenicity and efficacy against perinatal transmission. In F. Hollinger, S. Lemon, and H. Margolis (ed.). Viral hepatitis and liver disease. The Williams & Wilkins Co., Baltimore, Md.
72. Hyams, K. C. 1995. Risk of chronicity following acute hepatitis B virus infection. Clin. Infect. Dis. 20:992-1000.
73. Hyams, K. C., M. A. al-Arabi, A. A. al-Tagani, J. F. Messiter, A. A. al-Guali, and J. F. George. 1989. Epidemiology of hepatitis B in the Gezira region of Sudan. Am. J. Trop. Med. Hyg. 40:200-206.
74. Hyams, K. C., N. M. Osman, E. M. Khaled, A. A. Koraa, I. Z. Imam, N. M. el Ghorab, M. A. Dunn, and J. N. Woody. 1988. Maternal infant transmission of hepatitis B in Egypt. J. Med. Virol. 24:191-197.
75. Ip, N. M. H., P. N. Lelie, V. C. W. Wong, M. C. Kuhns, and H. W. Reesink. 1989. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 152:817-822.
76. Jilg, W., M. Schmidt, and F. Deinhardt. 1988. Persistence of specific antibodies after hepatitis B vaccination. J. Hepatol. 6:201-207.
77. Kaneko, S., R. H. Miller, and A. M. Di Bisceglie. 1990. Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Gastroenterology 99:799-804.
78. Kann, M., and W. H. Gerlieh. 1997. Replication of hepatitis B virus, p. 63-116. In T. J. Harrison and A. J. Zuckerman (ed.), The molecular medicine of viral hepatitis. John Wiley & Sons, Inc., New York, N.Y.
79. Komani, K., and M. E. Peeples. 1990. Physiology and function of the Vero cell receptor for the hepatitis B small S protein. Virology 177:332-338.
80. Korenman, J., B. Baker, J. Wagonner, J. E. Everhart, A. M. Di Bisceglie, and J. H. Hoofnagle. 1991. Long term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 114:629-634.
81. Krugman, S., and J. P. Giles. 1973. Viral hepatitis, type B (MS-2 strain): further observations on natural history and prevention. N. Engl. J. Med. 288:755-760.
82. Krugman, S., J. P. Giles, and J. Hammond. 1967. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 200:365-373.
83. Krugman, S., J. P. Giles, and J. Hammond. 1970. Viral hepatitis type B: heat on the infectivity and antigenicity of the MS-2 strains. J. Infect. Dis. 122:432-436.
84. Krugman, S., J. P. Giles, and J. Hammond. 1971. Viral hepatitis type B: prevention with specific hepatitis B immune serum globulin. JAMA 218: 1665-1670.
85. Krugman, S., J. P. Giles, and J. Hammond. 1971. Viral hepatits type B MS-2 strain): studies on active immunization. JAMA 217:41-45.
86. Lau, J. Y. N., and T. L. Wright. 1993. Molecular virology and pathogenesis of hepatitis B. Lancet 342:1335-1340.
87. Lee, C.-L., and Y.-C. Ko. 1997. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 99:351-353.
88. Lee, C. Y., L. M. Huang, M. H. Chang, C. Y. Hsu, S. J. Wu, J. L. Sung, and A. Safary. 1991. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr. Infect. Dis. J. 10:299-303.
89. Lee, P. I., C. Y. Lee, L. M. Huang, and M. H. Chang. 1995. Long term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J. Pediatr. 126:716-721.
90. Lee, S. D., K. J. Lo, J. C. Wu, Y. T. Tsai, J. Y. Wang, L. P. Ting, and M. J. Tong. 1986. Prevention of maternal-infant hepatitis B transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 6:369-373.
91. Leenders, W. H., H. L. Glansbeek, W. C. Bruin, and S. H. Yap. 1990. Binding of the major and large HBsAg to human hepatocytes and liver plasma membranes: putative external and internal receptors for infection and secretion of hepatitis B virus. Hepatology 12:141-147.
92. Liaw, Y.-F., D.-I. Tai, C.-M. Chu, and T.-J. Chen. 1988. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8:493-496.
93. Lieming, D., Z. Mintai, W. Yinfu, Z. Shaochin, K. Weiqin, and A. Smego. 1993. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin. Infect. Dis. 17:475-479.
94. Lingan, A. L., E. O. Domingo, S. West, C. M. Reyes, S. Gasmen, G. Viterbo, E. Tiu, and M. A. Langsang. 1986. Seroepidemiology of hepatitis B virus in the Phillipines. Am. J. Epidemiol. 123:473-480.
95. Lo, K. J., S. D. Lee, Y. T. Tsai, T. C. Wu, C. Y. Chan, G. H. Chen, and C. L. Yeh. 1988. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg positive H BsAg-carrier mothers. Hepatology 8: 1647-1650.
96. Lo, K. J., Y. T. Tsai, S. D. Lee, T. C. Wu, J. Y. Wang, G. H. Chen, C. L. Yeh, B. N. Chiang, S. H. Yeh, and A. Goudeau. 1985. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J. Infect. Dis. 152:817-822.
97. Lok, A. S. F., H.-T. Chung, V. W. S. Liu, and O. C. K. Ma. 1993. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha. Gastroenterology 105:1833-1838.
98. Lok, A. S. F., C. Lai, P. C. Wu, V. C. Wong, E. K. Yeoh, and H. J. Lin. 1987. Hepatitis B virus infection in Chinese families in Hong Kong. Am. J. Epidemiol. 126:191-197.
99. Lok, A. S. F., and C.-L. Lai. 1988. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive children. Hepatology 8:1130-1133.
100. Lurman, A. 1855. Eine icterus Epidemic. Berlin Klin. Wochenschr. 22:20-23.
101. MacCallum, F. O., and D. J. Bauer. 1947. Homologous serum hepatitis. Lancet ii:691-692.
102. MacCallum, F. O., and D. J. Bauer. 1944. Homologous serum jaundice: transmission experiments with human volunteers. Lancet i:622-627.
103. Magnius, L. O., and J. A. Espmark. 1972. New specificities in Australia antigen-positive sera distinct from the Le Bouvier determinants. J. Immunol. 109:1017-1021.
104. Mahoney, F., N. Smith, M. J. Allter, and H. Margolis. 1997. Progress towards the elimination of hepatitis B virus transmission in the United States. Viral Hepatitis Rev. 3:105-119.
105. Mahoney, F., B. Woodruff, J. Erbett, P. Coleman, E. Reid, G. Schatz, and M. Kane. 1993. Evaluation of a hepatitis B immunization program on the prevalence of hepatitis B in virus infection. J. Infect. Dis. 167:203-207.
106. Mahoney, F. J., M. Lawrence, L. McFarland, C. Scott, Q. Le, and T. Farley. 1995. Continuing transmission of hepatitis B virus infection among U.S.-born Southeast Asian children. Pediatrics 96:1113-1116.
107. Mahoney, F. J., K. Stewart, H. Hu, P. Coleman, and M. J. Alter. 1997. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch. Intern. Med. 157:2601-2605.
108. Mahoney, F. J., B. Woodruff, A. Auerbach, A. Polloi, J. McCready, M. Durand, K. Aniol, E. Reed, I. Williams, and E. Pretrick. 1996. Progress on the elimination of hepatitis B virus transmission in Micronesia and American Samoa. Pac. Health Dialog 1996:140-46.
109. Margolis, H. S., M. J. Alter, and S. C. Hadler. 1991. Hepatitis B: evolving epidemiology and implications for control. Semin. Liver Dis. 11:84-92.
110. Margolis, H. S., P. J. Coleman, R. E. Brown, E. E. Mast, S. H. Sheingold, and J. A. Arevalo. 1995. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 274:1201-1208.
111. Marinier, E., V. Barrois, B. Larouze, W. T. London, A. Cofer, L. Diakhate, and B. S. Blumberg. 1985. Lack of perinatal transmission of hepatitis B virus infection in Senegal, West Africa. J. Pediatr. 106:843-849.
112. Maynard, J. E., M. A. Kane, M. J. Alter, and S. C. Hadler. 1988. Control of hepatitis B by immunization: global perspectives. Grune and Stratton Inc., New York, N.Y.
113. McLean, A. A., M. R. Hilleman, W. J. McAleer, and E. B. Buynak. 1983. Summary of worldwide clinical experience with H-B-Vax (B, MSD). J. Infect. 1(Suppl.):95-104.
114. McMahon, B., E. R. Rhoades, W. L. Heyward, E. Tower, D. Ritter, A. P. Lanier, R. B. Wainwright, and C. Helminiak. 1987. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet ii:1134-1136.
115. McMahon, B. J., S. R. Alberts, R. B. Wainwright, L. Bulkow, and A. P. Lanier. 1990. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface ant igen-positive Alaska native carriers. Arch. Intern. Med. 150:1051-1054.
116. McMahon, B. J., W. L. M. Alward, D. B. Hall, W. L. Heyward, T. R. Bender, D. P. Francis, and J. E. Maynard. 1985. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J. Infect. Dis. 151:599-603.
117. McMahon, G., P. H. Ehrlich, Z. A. Moustafa, L. A. McCarthy, D. Dottavio, M. D. Tolpin, P. I. Nadler, and L. Ostberg. 1992. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 15:757-766.
118. McQuillan, G. M., T. R. Townsend, H. A. Fields, M. Carrol, M. Leahy, and B. F. Polk. 1989. Seroepidemiology of hepatitis B virus in the United States, 1976 to 1980. Am. J. Med. 87(Suppl.):5-10.
119. Milne, A., G. K. Allwood, C. D. Moyes, N. E. Pearce, and C. R. Lucas. 1985. Prevalence of hepatitis B infections in a multiracial New Zealand community. N. Z. Med. J. 10:529-532.
120. Milne, A., S. Krugman, J. A. Waldon, S. C. Hadler, C. R. Lucas, C. D. Moves, and N. E. Pearce. 1992. Hepatitis B vaccination in children: five year booster study. N. Z. Med. J. 105:336-338.
121. Milne, A., and J. Waldon. 1992. Recombinant DNA hepatitis B vaccination in teenagers: effect of a booster does at 5 and a half years. J. Infect. Dis. 166: 942.
122. Moulia-Pelat, J. P., A. Spiegel, P. M. Martin, R. Cardines, J. P. Boutin, J. F. Roux, J. L. Excler, and P. Saliou. 1994. A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years. Vaccine 12:499-502.
123. Nainan, O. V., C. E. Stevens, and H. S. Margolis. 1996. Hepatitis B virus (HBV) antibody resistant mutants: frequency and significance, p. 29. In Ninth Triennial International Symposium on Viral Hepatitis and Liver Disease.
124. Neefe, J. R., S. S. Gellis, and J. Stokes. 1946. Homologous serum hepatitis and infectious (epidemic) hepatitis: studies in volunteers bearing on immunological and other characteristics of etiologic agents. Am. J. Med. 1:3-22.
125. Neurath, A. R., S. B. Kent, N. Strict and K. Parker. 1986. Identification and chemical synthesis of a host cell receptor binding cite on hepatitis B virus. Cell 46:429-436.
126. Ogata, N., R. H. Miller, K. G. Ishak, A. R. Zanetti, and R. H. Purcell. 1993. Genetic and biologic characterization of two hepatitis B virus variants: a precore mutant implicated in fulminant hepatitis and a surface mutant resistant to immunoprophylaxis. Springer Verlag, Tokyo, Japan.
127. Oon, C. J. 1996. Studies on the transmissability of HBV vaccine escape 145 Gly to Arg mutants in immune and hepatitis B carriers, p. 265. In Ninth Triennial International Symposium on Viral Hepatitis and Liver Disease.
128. Polish, L. B., C. N. Shapiro, F. Bauer, P. Klotz, P. Ginier, R. R. Roberto, H. S. Margolis, and M. J. Alter. 1992. Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger-stick device. N. Engl. J. Med. 326:721-725.
129. Pongpipat, D., V. Suvatte, and A. Assateerawats. 1989. Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. Asian Pac. J. Allergy Immunol. 7:37-40.
130. Pontisso, P., M. A. Petit, M. J. Bankowski, and K. Peeples. 1989. Human liver plasma membranes contain receptors for the hepatitis B virus pre-s1 region and, via polymerized human serum albumin, for the pre-s2 region. J. Virol. 63:1981-1988.
131. Poovorawan, Y., S. Sanpavat, S. Chumdermpadetsuk, and A. Safary. 1997. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch. Dis. Child. Fetal Neonatal Ed. 77:F47-F51.
132. Poovorawan, Y., S. Sanpavat, W. Pongpunglert, S. Chumdermpadetsuk, P. Sentrakul, P. Vandepapeliere, and A. Safary. 1992. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr. Infect. Dis. J. 11:816-821.
133. Prince, A. M. 1968. An antigen detected in the blood of patients during the incubation of serum hepatitis. Proc. Natl. Acad. Sci. USA 60:814-821.
134. Prince, A. M., H. Ikram, and T. P. Hopp. 1982. Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc. Natl. Acad. Sci. USA 79:579-582.
135. Redeker, A. G., J. W. Mosley, D. J. Gocke, A. P. McKee, and W. Pollack. 1975. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N. Engl. J. Med. 293:1055-1059.
136. Reyes, G. R., M. A. Purdy, J. P. Kim, K. C. Luk, L. M. Young, K. E. Fry, and D. W. Bradley. 1990. Isolation of a cDNA clone from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 248:1335-1339.
137. Rich, A. R. 1930. The pathogenesis of the forms of jaundice. Bull. Johns Hopkins Hosp. 47:338-377.
138. Rizzetto, M., M. G. Canese, J. Arico, O. Crivelli, F. Bonino, C. G. Trepo, and G. Verme. 1977. Immunoflourescent detection of a new antigen-antibody system (delta-antidelta) associated to the hepatitis B virus in the liver and serum of HBsAg carriers. Gut 18:997-1003.
139. Roome, A. J., S. J. Walsh, M. L. Cartter, and J. L. Hadler. 1993. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 270:2931-2934.
140. Ruff, T. A., D. M. Gertig, B. F. Otto, I. D. Gust, A. Sutanto, T. I. Soewarso, N. Kandun, I. C. Marschner, and J. E. Maynard. 1995. Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in Indonesia. J. Infect. Dis. 171:290-296.
141. Seeff, L. B., G. W. Beebe, J. H. Hoofnagle, J. E. Norman, Z. Buskell-Bales, J. G. Waggoner, N. Kaplowitz, R. S. Koff, J. L. Petrini, Jr., E. R. Schiff, et al. 1987. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N. Engl. J. Med. 316:965-970.
142. Stevens, C. E., R. A. Neurath, R. P. Beasley, and W. Szmuness. 1979. HBeAg and anti-HBe detection with radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J. Med. Virol. 3:237-241.
143. Stevens, C. E., P. E. Taylor, and M. J. Tong. 1988. Viral hepatitis and liver disease. Alan R. Riss, New York, N.Y.
144. Stevens, C. E., P. E. Taylor, M. J. Tong, P. T. Toy, G. N. Vyas, P. V. Nair, J. Y. Weissman, and S. Krugman. 1987. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 257:2612-2616.
145. Stevens, C. E., P. T. Toy, P. E. Taylor, T. Lee, and H. Y. Yip. 1992. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long term protection. Pediatrics 90(Suppl.):170-173.
146. Summers, J., P. M. Smith, and A. L. Horwich. 1990. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:2819-2824.
147. Sung, J. L. 1990. Hepatitis B eradication strategy for Asia. Vaccine 8(Suppl.):96-99.
148. Szmuness, W., C. E. Stevens, E. J. Harley, E. A. Zang, W. R. Olesko, D. C. Williams, R. Sadovsky, J. M. Morrison, and A. Kellner. 1980. Hepatitis B vaccine: demonstration of efficacy in a controlled trial in a high risk population in the U.S. N. Engl. J. Med. 303:833-841.
149. Taylor, P. E., and C. E. Stevens. 1988. Persistence of antibody to hepatitis B surface antigen after vaccination in healthy adults. Alan R. Liss, New York, N.Y.
150. Tin, K. 1987. In Symposium on Control of Hepatitis B in Infants and Children in High Risk Areas of the World, Whakatane, New Zealand.
151. Toukan, A. U., Z. K. Sharaiha, O. A. Abu-el-Rub, M. K. Hmoud, S. S. Dahbour, H. Abu-Hassan, S. M. Yacoub, S. C. Hadler, H. S. Margolis, P. J. Coleman, and J. E. Maynard. 1990. The epidemiology of hepatitis B virus among family members in the Middle East. Am. J. Epidemiol. 132:220-232.
152. Tsega, E., B. Mengesha, B.-G. Hansson, J. Lindberg, and E. Nordenfelt. 1986. Hepatitis A, B, and delta infection in Ethiopia: a serologic survey with demographic data. Am. J. Epidemiol. 123:344-351.
153. Ulrich, P. P., R. A. Bhat, B. Seto, D. Mack, J. Sninsky, and G. N. Vyas. 1989. Ezymatic amplification of hepatitis B virus DNA in serum compared with infectivity testing in chimpanzees. J. Infect. Dis. 160:37-43.
154. Virchow, R. 1865. Uber das Vorkommen und den Nachweiss des hepatogenen, insebesondere des Katarrhalischen Icterus. Virchows Ser. A 32:117-125.
155. Vyas, G. N., and P. O. Ulrich. 1991. Molecular characterization of genetic variants of hepatitis B virus. The Williams & Wilkins Co., Baltimore, Md.
156. Wainwright, R., L. R. Buklow, A. J. Parkinson, C. Zanis, and B. J. McMahon. 1997. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J. Infect. Dis. 175:674-677.
157. West, D. J. 1989. Clinical experience with hepatitis B vaccines. Am. J. Infect. Control 17:172-180.
158. West, D. J., and G. B. Calandra. 1996. Vaccine induced memory for hepatitis B surface antigen: implications for policy on booster caccination. Vaccine 14:1019-1027.
159. West, D. J., G. B. Calandra, T. M. Hesley, V. Idoli, and W. J. Miller. 1993. Control of hepatitis B through routine immunization of infants: the need for flexible schedules, and new combination vaccine formulations. Vaccine 11:S21-S27.
160. Wong, D. C., R. H. Purcell, and L. Rosen. 1979. Prevalence of antibody to hepatitis A and B in selected Pacific populations of the South Pacific. Am. J. Epidemiol. 110:227-236.
161. Wong, D. K. H., A. M. Cheung, K. O'Rourke, C. D. Naylor, A. S. Dersky, and J. Heathcote. 1993. Effect of alpha-interferon treatment in patients with B e antigen-positive chronic hepatitis B: a metanalysis. Ann. Intern. Med. 119:312-323.
162. Wong, V. C., H. M. Ip, H. W. Reesink, P. N. Lelie, E. E. Reerink-Brongers, C. Y. Yeung, and H. K. Ma. 1984. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet i:921-926.
163. Wood, R. C., K. L. MacDonald, K. E. White, C. W. Hedberg, M. Hanson, and M. T. Osterholm. 1993. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 270:2935-2972.
164. Xia, G., C. Liu, T. Yan, et al. 1995. Prevalence of hepatitis B virus markers in children vaccinated by hepatitis b vaccine in five hepatitis B vaccine experimental areas of China. Chin. J. Exp. Clin. Virol. 9:17-23.
165. Xu, Z.-Y., C.-B. Liu, D. P. Francis, R. H. Purcell, Z. L. Gun, S. C. Duan, R. J. Chen, H. S. Margolis, C. H. Huang, and J. E. Maynard. 1985. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized double-blind placebo-controlled and comparative trial. Pediatrics 76:713-718.
166. Zanetti, A. R., E. Tanzi, G. Manzillo, G. Maio, C. Sbreglia, N. Caporaso, H. Thomas, and A. J. Zuckerman. 1988. Hepatitis B variant in Europe. Lancet ii:1132-1133.
167. Zhi-yi, X. U., S.-D. Duan, and H. Margolis. 1995. Long term efficacy of postexposure immunization of infants for prevention of hepatitis B virus infection. J. Infect. Dis. 171:54-60.
168. Zuckerman, A. J., T. J. Harrison, and C. J. Oon. 1994. Mutation in S region of hepatitis B virus. Lancet 343:737-738.